Nutriband Inc
NTRB4.490USD
-0.040-0.88%
收盤 12/19, 16:00（美東）報價延遲15分鐘
54.58M總市值
虧損本益比TTM
關於 Nutriband Inc 公司
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc簡介
公司代碼NTRB
公司名稱Nutriband Inc
上市日期Jun 20, 2017
CEOMelnik (Serguei)
員工數量- -
證券類型Ordinary Share
年結日Jun 20
公司地址121 S Orange Ave Ste 1500
城市ORLANDO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編32801-3241
電話14073776695
網址https://nutriband.com/
公司代碼NTRB
上市日期Jun 20, 2017
CEOMelnik (Serguei)
Nutriband Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Sale of goods
622.45K
0.00%
Services
0.00
0.00%
地區USD
名稱
營收
佔比
United States
614.92K
98.79%
Non-United States
7.53K
1.21%
業務
地區
業務USD
名稱
營收
佔比
Sale of goods
622.45K
0.00%
Services
0.00
0.00%
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Botgros (Vitalie)
26.44%
TII Jet Services, LDA
14.85%
Sheridan (Gareth)
14.47%
Glinka (Serguei)
9.19%
Melnik (Serguei)
7.72%
其他
27.33%
持股股東
持股股東
佔比
Botgros (Vitalie)
26.44%
TII Jet Services, LDA
14.85%
Sheridan (Gareth)
14.47%
Glinka (Serguei)
9.19%
Melnik (Serguei)
7.72%
其他
27.33%
股東類型
持股股東
佔比
Individual Investor
59.53%
Corporation
14.85%
Investment Advisor
2.21%
Investment Advisor/Hedge Fund
0.82%
Research Firm
0.04%
其他
22.55%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
36
350.65K
2.91%
-71.29K
2025Q2
44
8.87M
79.52%
+489.89K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Botgros (Vitalie)
3.09M
25.65%
--
--
Jun 20, 2025
TII Jet Services, LDA
1.81M
15.02%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
14.64%
--
--
Jun 20, 2025
Glinka (Serguei)
825.00K
6.86%
--
--
Jun 20, 2025
Melnik (Serguei)
820.42K
6.82%
--
--
Jun 20, 2025
The Vanguard Group, Inc.
199.63K
1.66%
+600.00
+0.30%
Jun 30, 2025
Goodman (Gerald)
86.33K
0.72%
--
--
Jun 20, 2025
Geode Capital Management, L.L.C.
63.63K
0.53%
+81.00
+0.13%
Jun 30, 2025
Smith (Allan)
41.91K
0.35%
--
--
Jun 20, 2025
Patrick (Jeff)
36.61K
0.3%
--
--
Jun 20, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 29, 2022
Split
6→7
公告日期
類型
比率
Jul 29, 2022
Split
6→7
常見問題
Nutriband Inc的前五大股東是誰？
Nutriband Inc的前五大股東如下：
Botgros (Vitalie)持有股份：3.09M佔總股份比例：25.65%。
TII Jet Services, LDA持有股份：1.81M佔總股份比例：15.02%。
Sheridan (Gareth)持有股份：1.76M佔總股份比例：14.64%。
Glinka (Serguei)持有股份：825.00K佔總股份比例：6.86%。
Melnik (Serguei)持有股份：820.42K佔總股份比例：6.82%。
Botgros (Vitalie)持有股份：3.09M佔總股份比例：25.65%。
TII Jet Services, LDA持有股份：1.81M佔總股份比例：15.02%。
Sheridan (Gareth)持有股份：1.76M佔總股份比例：14.64%。
Glinka (Serguei)持有股份：825.00K佔總股份比例：6.86%。
Melnik (Serguei)持有股份：820.42K佔總股份比例：6.82%。
Nutriband Inc的前三大股東類型是什麼？
Nutriband Inc 的前三大股東類型分別是：
Botgros (Vitalie)
TII Jet Services, LDA
Sheridan (Gareth)
Botgros (Vitalie)
TII Jet Services, LDA
Sheridan (Gareth)
有多少機構持有Nutriband Inc(NTRB)的股份？
截至2025Q3，共有36家機構持有Nutriband Inc的股份，合計持有的股份價值約為350.65K，占公司總股份的2.91% 。與2025Q2相比，機構持股有所增加，增幅為-76.60%。
哪個業務部門對Nutriband Inc的收入貢獻最大？
在FY2026Q2，Sale of goods業務部門對Nutriband Inc的收入貢獻最大，創收622.45K，占總收入的--% 。
